Metástasis cutáneas de tumores sólidos. Estudio descriptivo retrospectivo

Sánchez, María Encarnación Gómez; Martínez, María Luisa Martínez; Hijas, María Carmen Martín De; Villaescusa, María Teresa López; Berruga, Cristina Faura; Vázquez, María Rodríguez; García, Lorenzo Juan Pérez

doi:10.1016/j.piel.2013.11.007

Cited by 4 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, Lookingbill et al [ 25 ] found that only 6.3% of patients with BC had cutaneous involvement at the time of diagnosis of the primary tumor. More recently, Johnson et al [ 24 ] reported that approximately 13.7% of the patients in the 9 retrospective series reviewed [ 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 ] had a skin lesion before or simultaneously with the diagnosis of BC. Supporting these observations, we found that 18.2% of patient in the present series debuted with skin involvement.…”

Section: Discussionmentioning

confidence: 99%

Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases

González-Martínez

Pizarro

Pérez-Míes

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: The characterization of molecular alterations of primary breast carcinomas (BC) and their cutaneous metastases (CM) to identify genes involved in the metastatic process have not yet been completely accomplished. Methods: To investigate the molecular alterations of BC and their CM, a total of 66 samples (33 BC and 33 CM) from 33 patients were analyzed by immunohistochemical and massive parallel sequencing analyses. In addition, the clinicopathological characteristics of patients and tumors were analyzed. Results: Triple negative (TN) BCs were overrepresented (36.4%) among tumors that developed CM. A change of tumor surrogate molecular type in metastases was found in 15% of patients and 48.5% of the CM presented some additional molecular alteration with respect to the primary tumor, the most frequent were amplification of MYC and MDM4, and mutations in TP53 and PIK3CA. Survival was related to histological grade, tumor surrogate molecular type and TP53 mutations in the univariate analysis but only the tumor surrogate molecular type remained as a prognostic factor in the multivariate analysis. Conclusions: The TN molecular type has a greater risk of developing skin metastases. There are phenotypic changes and additional molecular alterations in skin metastases compared to the corresponding primary breast tumors in nearly half of the patients. Although these changes do not follow a specific pattern and varied from patient to patient, they could impact on the treatment. More studies with larger patient and sample cohorts are needed.

show abstract